Journal article
Epidemiology of hepatitis B-associated hepatocellular carcinoma in Victoria
M Sinclair, S Roberts, W Kemp, V Knight, A Dev, P Gow, H Philpott, I Kronborg, NJ Arachchi, S Bell, L Lim, A Gorelik, A Nicoll
Internal Medicine Journal | WILEY | Published : 2013
DOI: 10.1111/imj.12068
Abstract
Background: Chronic hepatitis B (HBV) and cirrhosis are major risk factors for hepatocellular carcinoma (HCC). The proportion and characteristics of cases with cirrhosis are not well documented. Aim: Our aim was to compare demographic, viral and tumour characteristics of HBV-associated HCC in an Australian cohort, in patients with and without cirrhosis. Methods: Existing HCC databases at six Melbourne teaching hospitals were reviewed for cases associated with HBV. Patient demographics, HBV viral characteristics, presence of cirrhosis, serum alpha-fetoprotein and tumour size were assessed. Mode of diagnosis was recorded through surveillance or symptoms, and treatment was either palliative, pe..
View full abstractGrants
Funding Acknowledgements
S. Roberts: board memberships - Janssen, MSD, Roche, Gilead Sciences, Bristol Myer Squibb, Novartis; consultancy - Janssen, Roche. V. Knight: travel sponsorship - Bayer. A. Dev: research funding - Roche, Bristol Myer Squibb, Gilead Sciences; consultancy - Gilead Sciences, Bristol Myer Squibb, Bayer, MSD, Roche, Janssen. I. Kronborg: research support - BMS, MSD, Bayer, Gilead, Roche. N. J. Arachchi: travel grant - Bayer 2011. S. Bell: payment for lectures - Janssen, MSD; travel sponsorship - Gilead Sciences. A. Nicoll: research grant money received from MSD 2012; payment for lectures by MSD, Bayer, Pfizer, Roche 2011-2012; travel and accommodation to conference - Bayer 2011.